Fibrates Prevent Paclitaxel- and Carboplatin-Induced Vascular Endothelial Dysfunction

Share this content:

the Cancer Therapy Advisor take:

Paclitaxel and carboplatin (TCchem) are chemotherapy agents associated with vascular toxicities caused by unclear mechanisms. Cisplatin, a platinum-containing anti-cancer agent, is known to inhibit PPARα and damage the microvascular vessels in the kidneys.

Investigators conducted a pilot study to determine whether the systemic deficiency of PPARα, caused by TCchem, is the underlying mechanism for the vascular endothelial dysfunction.

In the study, there were 45 patients with gynecological cancer who were treated with TCchem and were grouped according to their triglyceride (TG) levels. Of the 30 patients exhibiting hypertriglyceridemia during TCchem, 11 patients were given bezafibrate; 15 patients exhibited stable TG levels. Endothelial dysfunction was evaluated by measuring the flow-mediated dilation (FMD) values and serum pentraxin-3 levels before and after the administration of TCchem. Human umbilical vein endothelial cells (HUVECs) were used to assess the biological mechanisms induced by TCchem via in vitro examinations.

The results showed that TCchem contributes to endothelial dysfunction by TG-dependent and TG-independent mechanisms. The administration of TCchem caused hypertriglyceridemia in 66% of patients, and in vitro examinations showed that TCchem reduced nitric oxide production and PPARα activity in HUVECs.

However, patients treated with TCchem followed by bezafibrate showed reduced TG levels, improved FMD%, and decreased serum pentraxin-3 levels. Overall, the findings indicate that bezafibrate, a PPARα agonist fibrate, can prevent endothelial dysfunction caused by TCchem.

Addition of sorafenib to standard chemotherapy for the treatment of younger patients with AML is eff
Paclitaxel and carboplatin (TCchem) are chemotherapy agents associated with vascular toxicities caused by unclear mechanisms.
The primary aim of this study was to evaluate whether TCchem induces vascular endothelial dysfunction via systemic PPARα deficiency. In addition, human umbilical vein endothelial cells (HUVECs) were used to elucidate the mechanisms responsible for TCchem-induced vascular toxicities.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters